Charles Ng

3.4k total citations · 1 hit paper
11 papers, 1.2k citations indexed

About

Charles Ng is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Charles Ng has authored 11 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 7 papers in Oncology and 2 papers in Genetics. Recurrent topics in Charles Ng's work include Melanoma and MAPK Pathways (8 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and CAR-T cell therapy research (2 papers). Charles Ng is often cited by papers focused on Melanoma and MAPK Pathways (8 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and CAR-T cell therapy research (2 papers). Charles Ng collaborates with scholars based in United States, Australia and Spain. Charles Ng's co-authors include Antoni Ribas, Roger S. Lo, Richard C. Koya, Thinle Chodon, Hubing Shi, Richard A. Scolyer, Xiangju Kong, Gatien Moriceau, Richard Kefford and Georgina V. Long and has published in prestigious journals such as Nature Communications, PLoS ONE and Biochemistry.

In The Last Decade

Charles Ng

11 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

2012 470 citations Hubing Shi, Gatien Moriceau et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Charles Ng United States	10	962	658	195	177	151	11	1.2k
Inna V. Fedorenko United States	16	1.3k 1.4×	809 1.2×	238 1.2×	190 1.1×	195 1.3×	27	1.6k
Jan Martin United Kingdom	6	843 0.9×	431 0.7×	146 0.7×	98 0.6×	92 0.6×	7	1.0k
Jessica Hyman Australia	7	738 0.8×	762 1.2×	145 0.7×	126 0.7×	258 1.7×	8	1.1k
Madhavi Tadi United States	7	849 0.9×	429 0.7×	138 0.7×	175 1.0×	96 0.6×	7	1.0k
Maurizia Dalla Palma Italy	11	750 0.8×	454 0.7×	123 0.6×	142 0.8×	80 0.5×	19	974
Darin Smith United States	12	705 0.7×	316 0.5×	98 0.5×	112 0.6×	95 0.6×	13	978
Aayoung Hong United States	9	1.5k 1.5×	1.0k 1.5×	273 1.4×	238 1.3×	301 2.0×	11	1.8k
Fernando Salangsang United States	6	611 0.6×	401 0.6×	101 0.5×	75 0.4×	66 0.4×	13	775
Patrícia Volpe United States	4	963 1.0×	639 1.0×	108 0.6×	157 0.9×	156 1.0×	6	1.3k
Wanleng Deng United States	14	907 0.9×	659 1.0×	85 0.4×	93 0.5×	171 1.1×	20	1.4k

Countries citing papers authored by Charles Ng

Since Specialization

Citations

This map shows the geographic impact of Charles Ng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Ng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Ng more than expected).

Fields of papers citing papers by Charles Ng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Ng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Ng. The network helps show where Charles Ng may publish in the future.

Co-authorship network of co-authors of Charles Ng

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Ng. A scholar is included among the top collaborators of Charles Ng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Ng. Charles Ng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Atefi, Mohammad, Bjoern Titz, Jennifer Tsoi, et al.. (2016). CRAF R391W is a melanoma driver oncogene. Scientific Reports. 6(1). 14 indexed citations

2.

Atefi, Mohammad, Bjoern Titz, Earl Avramis, et al.. (2015). Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma. Molecular Cancer. 14(1). 27–27. 51 indexed citations

3.

Ma, Chao, Ann Cheung, Thinle Chodon, et al.. (2013). Multifunctional T-cell Analyses to Study Response and Progression in Adoptive Cell Transfer Immunotherapy. Cancer Discovery. 3(4). 418–429. 112 indexed citations

4.

Shi, Hubing, Aayoung Hong, Xiangju Kong, et al.. (2013). A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discovery. 4(1). 69–79. 133 indexed citations

5.

Escuin-Ordinas, Helena, Mohammad Atefi, Yong Fu, et al.. (2013). COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Molecular Oncology. 8(2). 250–260. 31 indexed citations

6.

Escuin-Ordinas, Helena, Mark Elliott, Mohammad Atefi, et al.. (2013). PET imaging to non-invasively study immune activation leading to antitumor responses with a 4-1BB agonistic antibody. Journal for ImmunoTherapy of Cancer. 1(1). 14–14. 14 indexed citations

7.

Shi, Hubing, Gatien Moriceau, Xiangju Kong, et al.. (2012). Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications. 3(1). 724–724. 470 indexed citations breakdown →

8.

Euw, Erika von, Mohammad Atefi, Narsis Attar, et al.. (2012). Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Molecular Cancer. 11(1). 22–22. 61 indexed citations

9.

Niehr, Franziska, Erika von Euw, Narsis Attar, et al.. (2011). Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. Journal of Translational Medicine. 9(1). 76–76. 78 indexed citations

10.

Atefi, Mohammad, Erika von Euw, Narsis Attar, et al.. (2011). Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway. PLoS ONE. 6(12). e28973–e28973. 183 indexed citations

11.

Villareal, Valerie A., Charles Ng, Sabrina C. Ward, et al.. (2010). Anthrax Toxin Receptor 1/Tumor Endothelial Marker 8: Mutation of Conserved Inserted Domain Residues Overrides Cytosolic Control of Protective Antigen Binding. Biochemistry. 49(34). 7403–7410. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact